Palbociclib (Ibrance®) for the treatment of metastatic breast cancer

The National Health Care Institute carried out an assessment of the medicine palbociclib (Ibrance®), whereby they came to the following conclusion.

The National Health Care Institute advises the Minister of WVS not to include palbociclib in the insured package, unless the product’s cost-effectiveness can be improved and the impact on the care budget reduced by means of price negotiations